[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
C4x Discovery Holdings Plc LSE:C4XD London Ordinary Share GB00BQQ2RV18 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.10 0.3% 33.10 33.00 34.90 34.30 33.00 33.00 262,647 11:24:21
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -5.9 -2.0 - 75

C4X Discovery Holdings PLC Clive Dix wins Scrip Lifetime Achievement Award

03/12/2021 10:34am

RNS Non-Regulatory


TIDMC4XD

C4X Discovery Holdings PLC

03 December 2021

C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

Clive Dix receives the Scrip Lifetime Achievement Award 2021

3 December 2021 - C4X Discovery Holdings plc (AIM: C4XD), is delighted to announce that its Chief Executive Officer, Dr Clive Dix together with Dame Kate Bingham, the leaders of the UK Vaccine Taskforce, have won the Lifetime Achievement Award at the 2021 Scrip Awards. The Scrip Awards applaud the essential role that the pharmaceutical, biotech and other allied industries play in improving healthcare.

Eva-Lotta Allan, Chairman of C4X Discovery, said: "We are very proud of this significant achievement by both Clive and Kate and we are thankful for the incredibly important work that they and the whole of the UK Vaccine Taskforce have carried out. Throughout his impressive career, Clive has contributed significantly to the industry and to us, at C4XD, his drive and determination to best serve patients is what makes Clive the great leader and CEO that he is and everyone at C4XD is delighted to see them all recognised through the Scrip Lifetime Achievement Award."

- Ends -

Contacts

 
 C4X Discovery Holdings 
 Mo Noonan, Communications                    +44 (0)787 6444977 
 
 Panmure Gordon (UK) Limited (NOMAD and 
  Broker) 
 Freddy Crossley, Emma Earl (Corporate 
  Finance)                                    +44 (0)20 7886 2500 
 Rupert Dearden (Corporate Broking) 
 
 C4X Discovery Media - Consilium Strategic 
  Communications 
 Mary-Jane Elliott, Chris Gardner, Matthew 
  Neal                                        +44 (0)203 709 5700 
 

Notes to Editors:

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world--leading medicines, which are developed by our partners for the benefit of patients. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, neurodegeneration, oncology and addictive disorders . Our commercially attractive portfolio ranges from early stage novel target opportunities to late stage Drug Discovery programmes ready for out-licensing to partners and we have two commercially partnered programmes with one candidate in clinical development.

We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development. Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio. For more information visit us at www.c4xdiscovery.com or follow us on twitter @C4XDiscovery .

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAUOURRAKUURAA

(END) Dow Jones Newswires

December 03, 2021 05:34 ET (10:34 GMT)

1 Year C4x Discovery Chart

1 Year C4x Discovery Chart

1 Month C4x Discovery Chart

1 Month C4x Discovery Chart
ADVFN Advertorial
Your Recent History
LSE
C4XD
C4x Discov..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220125 12:16:45